Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 11;29(5):3472-3488.
doi: 10.3390/curroncol29050280.

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review

Valentina Baro  1 , Giulia Cerretti  2 , Michela Todoverto  1 , Alessandro Della Puppa  3 , Franco Chioffi  4 , Francesco Volpin  4 , Francesco Causin  5 , Fabio Busato  6 , Pasquale Fiduccia  7 , Andrea Landi  1 , Domenico d'Avella  1 , Vittorina Zagonel  2 , Luca Denaro  1 , Giuseppe Lombardi  2
Affiliations
Review

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review

Valentina Baro et al. Curr Oncol. .

Abstract

Glioblastomas with multiple foci at presentation (mGBMs) account for 2-35% of all GBMs. mGBMs have limited existing data and no standardized treatment. This study aims to determine their incidence, demographic and clinical features, outcome, and prognostic factors in terms of overall survival. We performed a monocentric retrospective study, reviewing patients treated at the Istituto Oncologico Veneto. Inclusion criteria were: new diagnosis of GBM and presence of multiple lesions on pre-treatment MRI. ECOG PS was used to evaluate clinical condition, RANO criteria for radiological assessment, and CTCAE v5.0 for treatment-related adverse events. The incidence of newly diagnosed mGBM was 7.2% and the study population consisted of 98 patients. Median age was 63 years, M:F ratio of 1.8:1, and a surgical approach was undertaken in 73 patients (mostly partial resection). MGMT was methylated in 47.5%, and 82 patients received active oncological treatment (65.9% radiotherapy plus temozolomide (RT + TMZ)). The disease control rate with RT + TMZ was 63%. Median OS of the entire study population was 10.2 months (95% CI 6.6-13.8), and median PFS was 4.2 months (95% CI 3.2-5.2). The ECOG PS, the extent of resection, and the RT + TMZ were significant prognostic factors in the univariate analysis for OS, but only the RT + TMZ was a significant independent OS predictor in the multivariate analysis (HR = 3.1, 95% IC 1.3-7.7, p = 0.014). The incidence of mGBM is not rare. RT + TMZ is confirmed to be an independent prognostic factor for survival and a safe and effective treatment. When feasible, RT + TMZ should be considered as a possible first-line treatment. The role of the extent of resection is still unclear.

Keywords: glioblastoma; multicentric; multifocal; oncology; surgery; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of the patient selection process.
Figure 2
Figure 2
Overall survival of the study population (median OS = 10.2 months).
Figure 3
Figure 3
OS Kaplan-Meier curves for the RT + TMZ: yes (median OS = 13.8 months) vs. no (median OS = 3.6 months).
See this image and copyright information in PMC

References

    1. Ostrom Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-oncology. 2020;22:iv1–iv96. doi: 10.1093/neuonc/noaa200. - DOI - PMC - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Laws J.E.R., Parney I., Huang W., Anderson J.F.A., Morris A.M., Asher A., Lillehei K.O., Bernstein M., Brem H., Sloan A.E., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J. Neurosurg. 2003;99:467–473. doi: 10.3171/jns.2003.99.3.0467. - DOI - PubMed
    1. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., De Tribolet N., Weller M., Stupp R. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N. Engl. J. Med. 2005;352:997–1003. doi: 10.1056/NEJMoa043331. - DOI - PubMed
    1. Salvati M., Caroli E., Orlando E.R., Frati A., Artizzu S., Ferrante L. Multicentric glioma: Our experience in 25 patients and critical review of the literature. Neurosurg. Rev. 2003;26:275–279. doi: 10.1007/s10143-003-0276-7. - DOI - PubMed

MeSH terms